Abstract:
The aim of this study was to identify predictor sets of genes whose over-or under-expression in human sporadic adrenocortical tumors would help to identify malignant versus benign tumors and to predict post-surgical metastatic recurrence. For this, we analyzed the expression of 230 candidate genes using cDNA microarrays in a series of 57 well characterized human sporadic adrenocortical tumors (33 adenomas and 24 carcinomas). We identified two clusters of genes (the IGF2 cluster containing 8 genes including IGF2, and the Steroidogenesis cluster containing 6 genes encoding steroidogenic enzymes plus 8 other genes) whose combined levels of expression appeared as good predictors of malignancy. This predictive value was as strong as that of the pathological score of Weiss. The analysis of the population of carcinomas (13 tumors) for genes whose expression would be strongly different between recurring and non-recurring tumors allowed the identification of 14 genes meeting these criteria. Among these genes, there are probably new markers of tumor evolution that will deserve further validation on a larger scale. Taken together, these results show that the parallel analysis of the expression levels of a selected group of genes on microgram quantities of tumor RNA (a quantity that can be obtained from fine-needle aspirations) appears as a complementary method to histopathology for the diagnosis and the prognosis of evolution of adrenocortical carcinomas.
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Introduction:
Although adrenocortical tumors are highly prevalent in the human population (3 to 7% at autopsy and/or in radiological series), only a small proportion cause endocrine disorders and less than 5% are malignant (1, 2). Many of the tumors that do not secrete aberrant levels of steroids are now discovered as incidentalomas (3) . The most frequent clinical presentations of adrenocortical adenomas and carcinomas are Cushing's syndrome (hypersecretion of glucocorticoids) with or without associated androgen secretion and virilism, and Conn's syndrome caused by small adenomas (less than 20 mm in size) exclusively secreting aldosterone. Estrogen-producing tumors are rare and usually malignant. About 50% of adrenocortical carcinomas secrete steroid precursors with reduced bioactivity. On average, adrenocortical carcinomas are diagnosed rather late at a stage when the tumor has often already spread occult or detectable metastases. The prognosis of adrenocortical carcinomas is therefore very poor with a mean patient survival rate of 20% at 5 years (4).
Despite some recent progress, the understanding of the biology of adrenocortical tumors is still partial. Clonal composition analyses and comparative genomic hybridization experiments have established that adrenocortical tumorigenesis is a multistep process resulting from sequential genetic alterations leading to progression from normal to adenomatous and, eventually, to malignant phenotypes (5) (6) (7) (8) . Several studies have demonstrated an increased frequency of DNA copy number changes in large malignant tumors that are infrequent in small benign lesions. The most common modification, observed in 85% of carcinomas, is the overexpression of the insulin-like growth factor II (IGF2) gene, that is associated with paternal isodisomy at the 11p15 locus (9, 10). However, the high number of chromosomal alterations and dysregulations of gene expression that are observed suggests that each tumor is potentially distinct from all others at the molecular and clinical levels (8, 9, 11, 12). Prognosis is thus not likely to be associated with abnormal expression of a single gene but rather with the combined disturbances of several genes. Massively parallel molecular analyses should then be developed in order to identify such combinations of misexpressed genes. The recently developed cDNA array technology, which allows the simultaneous analysis of mRNA expression levels of hundreds of genes, may be the method of choice. Several recent studies have demonstrated that the determination of gene expression signatures among clinically and histologically homogeneous groups of tumors permits the identification of subgroups with different evolution prognosis (13) (14) (15) (16) (17) (18) .
The classification of adrenocortical tumors between adenomas and carcinomas relies on several criteria including the size of the resected tumor mass, the degree of invasiveness and the 4 histopathological examination. Tumors presenting with local or regional invasion and/or metastases (McFarlane stages III and IV) are unequivocally classified as malignant. Conversely, in the case of purely localized tumors, the diagnosis is based on histopathological examination using the criteria defined by Weiss (19, 20) . However, in ~30% of these tumors (1≤ Weiss score ≤3), histopathology is unable to provide an unambiguous answer. There is therefore a crucial need for additional reliable analyses that could help the clinician in diagnostic and subsequent therapeutic decisions. In a recent retrospective study on a large cohort of patients with sporadic adrenocortical tumors, the analysis of 3 molecular alterations (loss of heterozygosity at the 17p13 locus, uniparental disomy at the 11p15 locus and overexpression of the IGF2 gene) revealed that they were independent predictors of shorter disease-free survival in univariate analysis (9). In a multivariate analysis, histological grade (relative risk, 4.2) and 17p13 LOH (relative risk, 21.5) appeared to be independently associated with recurrence (9).
The aim of this study was to take advantage of the cDNA array technology to identify predictor sets of genes whose over-or under-expression in adrenocortical tumors would help, on one hand, to discriminate between benign and malignant tumors, and, on the other hand, to identify the subgroup of patients bearing carcinomas at high risk of recurrence, in whom adjuvant therapy may be applied. For this purpose, using cDNA microarrays, we analyzed the expression of 230 candidate genes in a series of 57 sporadic adrenocortical tumors from adult patients who had been carefully followed up by five medical centers within the French clinical network COMETE (COrtico & MEdullo-surrénales Tumeurs Endocrines). We identified two clusters of genes whose levels of expression appeared as good predictors of malignancy. Their combination improved their predictive value to a level similar to but not better than the pathological score of Weiss. In addition, we identified a set of 14 genes (including ITGB2, GZMA, and ATF1) that allowed to significantly predict metastatic recurrence among the 13 carcinomas included in the analysis.
Materials and Methods:
Tumor samples and RNA extraction: Table I .
Total RNA was extracted as previously described (21) Survival analysis was performed using the Kaplan-Meier method (24) and compared between groups using the log rank test (univariate analysis). The calculations were performed using StatView software.
Results:
Gene expression profiling of human adrenocortical tumors:
The mRNAs from 57 human adrenocortical tumor samples were hybridized with cDNA arrays carrying the 230 selected genes. The overall expression patterns of these 57 tumors were analyzed with hierarchical clustering and displayed in a color-coded matrix ( Figure 1A ). Tumor samples are classified on the horizontal axis and genes on the vertical axis and both are ordered on the basis of similarity of their expression profiles. Overall similarity of gene expression profiles is shown as a dendrogram where branch length is inversely correlated with similarity.
As shown in Figure 1B 
Disease-free survival analysis of the whole tumor population :
Out of the 57 patients whose tumor RNAs were analyzed on DNA microarrays, 8 had incomplete surgery and 9 had unsufficient follow-up. We could however include 40 patients in a retrospective study of recurrence-free survival. In this group, the median duration of follow-up was 33 months (range 4-97). For patients without recurrence, the minimal follow-up period was 12 months. The Kaplan-Meier estimate of disease-free survival was 82.5% at 2 years ( Figure 4A ). During the follow-up period, 4 patients died of metastatic recurrence. Seven patients (17.5%) underwent recurrence 2-10.5 months after initial surgery (median= 6.7 months).
Univariate analyses were performed using the Kaplan-Maier statistical method. We first analyzed recurrence-free survival as a function of the expression profile of each individual gene cluster. The results of Figure 2 were used to classify each individual tumor into two groups characterized by low or high expression of the considered cluster. The curves shown in Figure 4 clearly indicate that the IGF2 (p< 0.01) and Steroidogenesis (p< 0.01) clusters were significant predictors of malignancy. They were not as good predictors however as the pathological grade (Weiss score, Figure 4E ) as the rate of recurrence among the group of tumors presenting a Weiss score ≥4 was 54% whereas it was only about 40% among the groups that presented either a high level of expression of the IGF2 gene cluster or a low expression level of the Steroidogenesis cluster. However, the combination of these two latter gene clusters allowed the identification of a subpopulation of tumors with low expression of the Steroidogenesis cluster and high expression of the IGF2 cluster that presented the same risk of post-surgical recurrence as the group of tumors with a Weiss score ≥4 (Figures 4E and 4F ). This observation is the first demonstration for adrenocortical tumors that the analysis of the pattern of expression of a limited number of genes (22 genes in total) is as predictive as the pathological grading.
Analysis of the steroid secretion profiles:
Another question that can be adressed in this study is the relationship between the steroid secretion profiles and the genetic expression profiles of these tumors. Among the tumor population studied, 23 overproduced glucocorticoids, 2 overproduced mineralocorticoids, 17
had a mixed secretion profile and 8 were non-secreting. Three tumors overproduced androgens and 2 overproduced estrogens. As shown in Figure 5 , most glucocorticoid-secreting tumors (19 out of 23, 82%) presented a high level of expression of the Steroidogenesis cluster.
Unexpectedly however, most (16 out of 19; 84%) of these differentiated tumors presented a low level of expression of the IGF2 cluster. On the other hand, most tumors with a mixed steroid production profile and most non-secreting tumors preferentially expressed the IGF2 cluster at a high level and the steroidogenesis cluster at a low level. This may reflect the known observation that glucorticoid overproduction is observed more frequently in adenomas than in carcinomas (2, 4).
Disease-free survival analysis of adrenocortical carcinomas :
We then separately analyzed the group of carcinomas (Weiss score ≥4) and asked whether we could identify a gene cluster whose expression level could allow to discriminate between recurring and non-recurring tumors. Unfortunately, only 13 of these 24 carcinomas could be included in a retrospective study of recurrence-free survival as tumors that were already metastatic before surgery had to be excluded from the analysis. Supervised analysis using a Student T test at 3% risk lead to the identification of 14 genes whose expression levels were clearly distinct between recurring and non-recurring tumors (Table 3 ; Figure 6A ). These genes were not associated to any particular cluster ( Figure 1A , blue curve), probably because of the small number of samples. As shown in Figure 6B , the group of recurring carcinomas could be perfectly separated from the group of non-recurring tumors on the basis of overexpression (6 genes) or underexpression (8 genes) of these genes.
Discussion:
An increasing number of studies have suggested the usefulness of cDNA array-based gene expression profile determination for cancer classification and some of them have succeeded in bringing up novel prognostic information (13) (14) (15) (16) (17) (18) . Using this technology, we profiled a series of 57 human sporadic adrenocortical tumors using a set of candidate genes, the majority of which are implicated in oncogenesis or steroidogenesis. For 40 of these tumors, the follow-up and clinical information was sufficient to perform a retrospective study. We aimed at identifying groups of genes whose expression level would help, on one hand, to discriminate between benign and malignant tumors, and, on the other hand, to identify the subpopulation of carcinomas that are more likely to recur. antimitotic agents (30) . Two genes encode TGFß2, a member of the TGFß superfamily and its signalling serine/threonine kinase receptor TGFß-R1. TGFß1 is an autocrine factor produced by the adrenal cortex (31, 32) . It has no effect on the proliferation of steroidogenic cells but it strongly inhibits their steroidogenic activities through down-regulation of StAR and CYP17 expression (33, 34) . Although TGFß2 has been less characterized in this tissue, it is known to share the same type 1 and type 2 receptors as TGFß1, to signal through the phosphorylation of the same Smad proteins (Smad2 and Smad3) and to have similar inhibitory effects on adrenocortical steroidogenesis (our unpublished observations). It is tempting to speculate that the overexpression of TGFß2 and its type 1 receptor in adrenocortical carcinomas may participate in the dedifferentiation of these tumors. Indeed, in our study, 6 out of 8 non-secreting tumors presented with a high level of expression of the IGF2 cluster ( Figure 6 ). Another original observation in this study is the identification of a group of 14 genes whose expression level allowed to perfectly discriminate recurring from non-recurring tumors among the 13 carcinomas analyzed. Among these genes is ITGB2, encoding integrin ß2, a common subunit for several receptors specifically expressed at the surface of leukocytes (40) . Integrin ß2
Two independent clusters of genes (the IGF2 and
associates with distinct subunits to form αLß2, αMß2, αDß2 or αXß2 integrins. These integrins are receptors for ICAM1-4 and fibrinogen. Integrin αLß2 (LFA-1) plays an important role in the rolling of leukocytes at the surface of the endothelium and their extravasation, as a receptor for ICAM-1 and ICAM-2 (41). This increased expression of ITGB2 is therefore likely to reflect an increased tumor infiltration by leukocytes. Granzyme A, which is encoded by a gene belonging to this same cluster, is a trypsin-like serine protease that is secretd by T lymphocytes and participates in target cell lysis during cell-mediated immune response (42, 43).
Expression of GZMA, like that of ITGB2, is thus likely to reflect infiltration by immune cells.
The inflammatory status of the carcinoma at time of resection could thus represent an important parameter to take in consideration for the prediction of metastatic evolution. The third gene in this cluster that is expressed with markedly distinct intensities between recurring and non-recurring carcinomas is ATF1. This gene encodes a cAMP-dependent transcription factor of the CREB family that is ubiquitously expressed. It was recently shown to be expressed in the human tumor cell line NCI-H295R where, together with CREMτ, it functionally compensates for the lack of CREB (44). Figure   6A . The number of samples in each group (n) is indicated near each curve. The probability of significant difference between the survival rates of two groups was analyzed using the Wilcoxon test and is indicated in the lower right corner. Table 3 : Identity of the set of genes discriminating recurring from non-recurring carcinomas
